{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:26:01Z","timestamp":1792218361169,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xphs.2026.104161","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:28:12Z","timestamp":1768087692000},"page":"104161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the impact of in-line PES filters on subvisible particle formation during IV administration of IgG4 monoclonal antibody"],"prefix":"10.1016","volume":"115","author":[{"given":"Praval","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylour","family":"Treadwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandipan","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104161_bib0001","unstructured":"International Conference on Harmonization Q8 (R2) pharmaceutical development. 2009. https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf"},{"key":"10.1016\/j.xphs.2026.104161_bib0002","unstructured":"Guidance for industry: dosage and Administration section of labeling for Human prescription drug and biological products\u2014Content and format. Draft guidance 12-JAN-2023. U.S. Food and Drug Administration. Available fromhttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/dosage-and-administration-section-labeling-human-prescription-drug-and-biological-products-content."},{"key":"10.1016\/j.xphs.2026.104161_bib0003","unstructured":"Guidance for industry: mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application. U.S. Food and Drug Administration. 2018. Available from https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/mixing-diluting-or-repackaging-biological-products-outside-scope-approved-biologics-license."},{"key":"10.1016\/j.xphs.2026.104161_bib0004","unstructured":"WHO. Guidelines on stability testing of active pharmaceutical ingredients and finished pharmaceutical products. 2018; annex 10. Available from https:\/\/www.who.int\/publications\/m\/item\/trs1010-annex10"},{"key":"10.1016\/j.xphs.2026.104161_bib0005","unstructured":"Guidance for industry. In-use stability studies and associated labeling statements for multiple-dose injectable animal drug products. U.S. Food and Drug Administration;. 2020. Available fromhttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-242-use-stability-studies-and-associated-labeling-statements-multiple-dose-injectable-animal"},{"key":"10.1016\/j.xphs.2026.104161_bib0006","unstructured":"CPMP E. Note for guidance on in-use stability testing of human medicinal products CPMP. QWP\/2934\/99, September; 2001. Available from chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-use-stability-testing-human-medicinal-products_en.pdf"},{"issue":"1","key":"10.1016\/j.xphs.2026.104161_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jps.22739","article-title":"Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions","volume":"101","author":"Sreedhara","year":"2012","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104161_bib0008","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.xphs.2023.05.002","article-title":"Current industry best practice on in-use stability and compatibility studies for biological products","volume":"112","author":"Blumel","year":"2023","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104161_bib0009","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.xphs.2016.09.028","article-title":"Microparticles and nanoparticles delivered in intravenous saline and in an intravenous solution of a therapeutic antibody product","volume":"106","author":"Pardeshi","year":"2017","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104161_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086322","article-title":"Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro","volume":"9","author":"Rombach-Riegraf","year":"2014","journal-title":"PLoS One"},{"issue":"30","key":"10.1016\/j.xphs.2026.104161_bib0011","doi-asserted-by":"crossref","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","article-title":"Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses","volume":"287","author":"Joubert","year":"2012","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.xphs.2026.104161_bib0012","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/jps.20599","article-title":"Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation","volume":"95","author":"Hermeling","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104161_bib0013","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","article-title":"Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics","volume":"32","author":"Ahmadi","year":"2015","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.xphs.2026.104161_bib0014","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/jps.23224","article-title":"Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags","volume":"101","author":"Kumru","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104161_bib0015","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/jps.24413","article-title":"Dose levels in particulate containing formulations impact anti-drug antibody responses to murine monoclonal antibody in mice","volume":"104","author":"Shomali","year":"2015","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104161_bib0016","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.xphs.2018.07.022","article-title":"Expanding bedside filtration\u2014a powerful tool to protect patients from protein aggregates","volume":"107","author":"Werner","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104161_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-019-2618-z","article-title":"In-line filtration of intravenous infusion may reduce organ dysfunction of adult critical patients","volume":"23","author":"Schmitt","year":"2019","journal-title":"Critical care"},{"issue":"2","key":"10.1016\/j.xphs.2026.104161_bib0018","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijpharm.2015.10.082","article-title":"Particle contamination of parenteralia and in-line filtration of proteinaceous drugs","volume":"496","author":"Werner","year":"2015","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2026.104161_bib0019","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.xphs.2017.05.028","article-title":"Protein adsorption to in-line filters of intravenous administration sets","volume":"106","author":"Besheer","year":"2017","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104161_bib0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/0148607183007002156","article-title":"In vitro study of inline filtration of medications commonly administered to pediatric cancer patients","volume":"7","author":"Ennis","year":"1983","journal-title":"J Parent Enteral Nutrit"},{"issue":"7","key":"10.1016\/j.xphs.2026.104161_bib0021","first-page":"935","article-title":"Effect of inline filtration on the potency of low-dose drugs","volume":"37","author":"Butler","year":"1980","journal-title":"Am J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2026.104161_bib0022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2710.1999.00242.x","article-title":"Evaluation of the in-line filters for the intravenous infusion of amphotericin B fluid","volume":"24","author":"Hirakawa","year":"1999","journal-title":"J Clin Pharm Ther"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104161_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejps.2011.06.004","article-title":"Drug retention by inline filters\u2013Effect of positively charged polyethersulfone filter membranes on drug solutions with low concentration","volume":"44","author":"Gasch","year":"2011","journal-title":"Eur J Pharmaceut Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104161_bib0024","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/08880018.2020.1838011","article-title":"Association between in-line filtration and type I hypersensitivity reactions in pediatric oncology patients receiving intravenous etoposide","volume":"38","author":"Ronsley","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"10.1016\/j.xphs.2026.104161_bib0025","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.xphs.2021.06.022","article-title":"Assessing the utility of in-line intravenous infusion filters","volume":"110","author":"Ayres","year":"2021","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104161_bib0026","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/0018578719867660","article-title":"Drugs to Be used with a filter for preparation and\/or administration\u20142019","volume":"56","author":"Ipema","year":"2021","journal-title":"Hosp Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2026.104161_bib0027","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of formulations of commercially available antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104161_bib0028","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.memsci.2008.08.046","article-title":"Non-specific binding and saturation of Polysorbate20 with aseptic filter membranes for drug substance and drug product during mAbproduction","volume":"325","author":"Zhou","year":"2008","journal-title":"J Memb Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104161_bib0029","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejpb.2008.04.021","article-title":"Glycation during storage and administration of monoclonal antibody formulations","volume":"70","author":"Fischer","year":"2008","journal-title":"Eur J Pharmaceut Biopharmaceut"},{"key":"10.1016\/j.xphs.2026.104161_bib0030","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1685814","article-title":"Defining the right diluent for intravenous infusion of therapeutic antibodies","volume":"12","author":"Luo","year":"2020","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.xphs.2026.104161_bib0031","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/jps.23861","article-title":"Control of protein particle formation during ultrafiltration\/diafiltration through interfacial protection","volume":"103","author":"Callahan","year":"2014","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104161_bib0032","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.xphs.2020.10.036","article-title":"In-use interfacial stability of monoclonal antibody formulations diluted in saline i.v. bags","volume":"110","author":"Kannan","year":"2021","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:33:10Z","timestamp":1772721190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022354926000109"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104161","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the impact of in-line PES filters on subvisible particle formation during IV administration of IgG4 monoclonal antibody","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104161"}}